- Home
- AMRN
as 11-03-2025 9:59am EST
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
| Founded: | 1989 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 302.0M | IPO Year: | 1993 |
| Target Price: | $12.00 | AVG Volume (30 days): | 155.4K |
| Analyst Decision: | Strong Sell | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.08 - $20.90 | Next Earning Date: | 10-29-2025 |
| Revenue: | $226,733,000 | Revenue Growth: | -5.93% |
| Revenue Growth (this year): | -10.8% | Revenue Growth (next year): | -12.79% |
Latest Amarin Corporation plc News
AMRN Breaking Stock News: Dive into AMRN Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Amarin Corporation plc (NASDAQ:AMRN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$11.33
MT Newswires
3 days ago
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
Simply Wall St.
3 days ago
Amarin (AMRN): Deep Discount Reinforces Market Caution Despite Projected Earnings Growth
GuruFocus.com
4 days ago
Amarin Corp PLC (AMRN) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Zacks
4 days ago
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
MT Newswires
5 days ago
European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading
Associated Press Finance
5 days ago
Amarin: Q3 Earnings Snapshot
GlobeNewswire
5 days ago
Amarin Reports Third Quarter 2025 Financial Results
Compare AMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRN Amarin Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.